Refining Clinical Trial Design, Antigen Selection & Manufacturing Processes to Fast-Track Turnaround Times & Optimize Efficacy, Accelerating Individualized Therapies Towards Approval
The personalized cancer vaccine field is approaching a defining moment, with the industry eagerly anticipating the Phase 3 data of the Moderna/Merck trial. Beyond this, we continue to see growing momentum with new strategic collaborations, such as LigaChem Bio and BreezeBio advancing mRNA cancer vaccines, signaling growing confidence in the future of individualized immunotherapies.
Yet significant challenges remain. As innovation accelerates, organizations must overcome key challenges spanning development, manufacturing, delivery, and market access.
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, Transgene, and more, to share data-driven insights, benchmark strategies and forge long-term partnerships for driving personalized cancer vaccines closer to their first approval.
Join 80+ personalized cancer vaccine leaders to:
- Explore emerging clinical data shaping the future of individualized cancer immunotherapies
- Optimize neoantigen selection strategies to improve immunogenicity, response rates, and clinical outcomes
- Accelerate development timelines through advances in manufacturing, automation, and vein-to-vaccine workflows
- Establish commercially viable processes by addressing sustainable cost of goods and scalable production models
- Navigate evolving regulatory and clinical development pathways to support successful approval
Personalized cancer vaccines have the potential to transform cancer treatment and we are in a pivotal era where we might soon see the first approval. The summit provides a unique forum to exchange experiences, challenge assumptions, and discuss the opportunities and hurdles that remain on the path to broader patient impact. I am excited to contribute to these conversations and to learn from fellow innovators working to advance the next generation of cancer immunotherapies.
Chief Scientific Officer, Nykode Therapeutics
The Personalized Cancer Vaccine Summit is a one-of-a-kind annual meeting highly focused on a single key therapeutic intervention (Personalized Cancer Vaccines). This makes it highly topical and relevant to those in the field and those who are looking to learn about the field. The meeting attracts attendees and speakers across industry, academia, and government to share information and exchange developments in the field.
President & Chief Executive Officer, Geneos Therapeutics
This meeting is a valuable opportunity to share new insights from our work, exchange perspectives with others advancing the field, and spark new ideas for the future of personalized cancer vaccines.
Associate Director, Therapeutic Immunology & Protein Engineering, Moderna Therapeutics
Explore The Full 2026 Event Guide
- 19+ expert speakers from pioneering biopharma and leading academics, including Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Mayo Clinic, HDT Bio, and more
- Gain in-depth data-driven insights into optimizing neoantigen selection, improving clinical trial design and fast-tracking production turnaround times
- 4 interactive workshops and panel discussions to solve challenges in manufacturing, patient selection, clinical development and supply chain costs
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest breakthroughs shaping personalized cancer vaccine development, from novel target selection strategies, innovative vaccine modalities to clinical and commercial insights. Gain exclusive insights from industry leaders during data-driven presentations, interactive workshops, and expert panel discussions.
Partner With Us
Showcase your solutions alongside other leading service providers to a community dedicated to cutting-edge individualized therapy innovation. Position your brand at the heart of the biopharma deals and partnerships defining oncology immunotherapies.
Join Cancer Vaccine Experts
Connect with cancer vaccine innovators and engage in the hottest conversations propelling safe, efficacious and commercially viable vaccine development. During the dedicated networking sessions, make critical connections, and build meaningful collaborations.